Overview

Pembrolizumab-PET Imaging

Status:
Completed

Trial end date:
2020-09-01

Target enrollment:

Participant gender:

Summary

This is a two center, single arm, investigator sponsored trial (IST) with the PET tracer 89Zr-pembrolizumab to evaluate in vivo whole body distribution of 89Zr-Pembrolizumab in a registered indication: locally advanced metastatic melanoma or non-small cell lung cancer before Pembrolizumab treatment.

Phase:

N/A

Details

Lead Sponsor:

University Medical Center Groningen

Treatments:

Pembrolizumab